Evidence for the extent and oncological benefit of lymphadenectomy for esophageal cancer

被引:0
|
作者
Krauss, Dolores T.
Schmidt, Thomas
Bruns, Christiane J.
Fuchs, Hans F. [1 ,2 ]
机构
[1] Univ Cologne, Med Fak, Klin & Poliklin Allgemein Viszeral Thorax & Transp, Kerpener Str 62, D-50937 Cologne, Germany
[2] Univ Cologne, Uniklin Koln, Kerpener Str 62, D-50937 Cologne, Germany
来源
CHIRURGIE | 2025年
关键词
Esophagectomy; Early stage cancer; Lymph node metastases; Tumor staging; Surgical technique; LYMPH-NODE; ADENOCARCINOMA; SAFETY; RESECTION; EFFICACY; IMPACT;
D O I
10.1007/s00104-024-02215-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
The prognosis for esophageal cancer is determined in particular by the depth of infiltration (T stage) and lymph node metastasis (N status). In patients with locally advanced tumors, surgical resection is the current standard. The extent of the lymphadenectomy depends on the localization of the tumor, analogous to the choice of surgical technique. For adequate tumor staging and achievement of pN0 status, seven lymph nodes without tumor metastases are necessary by definition but the current guidelines recommend 20 lymph nodes as a benchmark in an expert consensus. Despite the importance of the lymph node status for the prognosis of the patient and the already standardized use of targeted imaging of sentinel lymph nodes in other oncological disciplines, there is neither a validated method nor sufficient evidence for the benefit of lymph node mapping in esophageal cancer. The discussion about the prognostic advantage of lymphadenectomy is particularly interesting in T1 early stage cancer. Due to the technical advances of interventional endoscopy in recent years, organ preservation using endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) has not only become possible but also safe to carry out and thus established as the standard with better functional results; however, if one or more risk factors are present, endoscopic ablation is no longer defined as curative and should be supplemented by further treatment, usually non-organ-preserving resection. The step from organ-preserving interventional treatment with a low complication rate to a surgical procedure with significant mortality and morbidity as well as functional limitations seems immense and requires optimization, especially in view of the technical developments of surgery in recent years. This can either aim to identify the risk of lymph node metastases more precisely or to minimize the morbidity/mortality and functional limitations of additive treatment procedures. Approaches to this are currently the subject of research and have already been safely applied in individual pilot projects.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Evidenz für Ausmaß und onkologischen Nutzen der Lymphadenektomie beim MagenkarzinomEvidence for the extent and oncological benefit of lymphadenectomy in gastric cancer
    Matthias Kelm
    Sven Flemming
    Christoph-Thomas Germer
    Florian Seyfried
    Die Chirurgie, 2025, 96 (4) : 281 - 287
  • [22] Evidenz für Ausmaß und onkologischen Nutzen der Lymphadenektomie beim PankreaskarzinomEvidence for the extent and oncological benefit of lymphadenectomy for pancreatic cancer
    Tobias Keck
    Die Chirurgie, 2025, 96 (4) : 288 - 292
  • [23] Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm
    Stiles, Brendon M.
    Mao, Jialin
    Harrison, Sebron
    Lee, Benjamin
    Port, Jeffrey L.
    Sedrakyan, Art
    Altorki, Nasser K.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 157 (06): : 2454 - +
  • [24] Lymphadenectomy extent is closely related to long-term survival in esophageal cancer
    Kang, Chang Hyun
    Kim, Young Tae
    Jeon, Sang-Hoon
    Sung, Sook-Whan
    Kim, Joo Hyun
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2007, 31 (02) : 154 - 159
  • [25] Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?
    Pisano, F.
    Gaya, J. M.
    Breda, A.
    Palou, J.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (08) : 1551 - 1556
  • [26] Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?
    F. Pisano
    J. M. Gaya
    A. Breda
    J. Palou
    World Journal of Urology, 2019, 37 : 1551 - 1556
  • [27] Lymphadenectomy for esophageal cancer
    Collard, JM
    ANNALES DE CHIRURGIE, 1996, 50 (02): : 121 - 129
  • [28] History and evidence for state of the art of lymphadenectomy in esophageal cancer surgery
    Schuring, Nannet
    Henegouwen, Mark I. van Berge
    Gisbertz, Suzanne S.
    DISEASES OF THE ESOPHAGUS, 2024, 37 (04)
  • [29] An evidence-based medicine review of lymphadenectomy extent for gastric cancer
    Yang, Sun Hu
    Zhang, You Cheng
    Yang, Ke Hu
    Li, You Ping
    He, Xiao Dong
    Tian, Jin Hui
    Lv, Ting Hong
    Hui, Ying Hua
    Sharma, Neel
    AMERICAN JOURNAL OF SURGERY, 2009, 197 (02): : 246 - 251
  • [30] An evidence-based medicine review of lymphadenectomy extent for gastric cancer
    Slim, Karem
    Vons, Corinne
    AMERICAN JOURNAL OF SURGERY, 2009, 198 (04): : 580 - 580